Elevance Health (ELV) has drawn investor attention after updating its connected cancer care model. The updated approach now relies more on predictive analytics, oncology navigators, and digital tools to support patients and coordinate care delivery.

Over the past year Elevance Health has combined product updates such as the refreshed cancer care model with a steady share price trend, delivering a 1 year total shareholder return of 39.71% alongside a year to date share price return of 6.09%. This contrasts with a weaker 3 year total shareholder return of a 14.77% decline and points to momentum that has been building more recently, despite a 9.70% share price pullback over the past 30 days.

If you are watching how AI and data driven healthcare tools are reshaping outcomes, it can be useful to see what else is out there through the 41 healthcare AI stocks

After a strong 1 year return and a recent pullback, Elevance Health now trades at a discount to both analyst targets and intrinsic value estimates. Is the market rightly cautious, or is it mispricing the cancer care and data push?

Most Popular Narrative: 16.3% Undervalued

The most followed Elevance Health narrative puts fair value at $449.10 versus a last close of $375.84, which frames the recent pullback in a very different light.

Strategic investments in digital consumer engagement and Carelon's diversified health services (e.g., pharmacy, care management, behavioral health) are accelerating revenue growth and providing higher-margin, recurring income streams, which should drive both topline and earnings diversity as industry healthcare spending and complexity continue to rise.

Want to know what has to happen for that fair value to add up? The narrative leans on measured revenue growth, firmer margins, and a lower future earnings multiple than many peers. The full breakdown shows exactly how those moving parts are expected to interact.

Result: Fair Value of $449.10 (UNDERVALUED)

However, Elevance Health still faces pressure from higher medical costs in ACA and Medicaid, as well as ongoing integration risks across its expanding Carelon businesses.

Next Steps

The sentiment around Elevance Health is cautiously optimistic, so it makes sense to check the numbers yourself and decide how convincing that feels. If you want a clear view of what investors are most excited about, take a closer look at the 4 key rewards.

Looking for more investment ideas beyond Elevance Health?

If Elevance Health has your attention, do not stop there. The right mix of other stocks could round out your portfolio and sharpen your edge.

• Target reliable compounding potential by focusing on businesses that combine quality with attractive pricing through the 55 high quality undervalued stocks.
• Build a steadier income stream by scanning for companies with robust payout profiles using the 9 dividend fortresses.
• Reduce overall portfolio volatility by concentrating on companies that score well on resilience through the 81 resilient stocks with low risk scores.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.